Receipt date: 12/09/2008

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
of a collection of information unless it contains a unit OMB.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Application Number		10518110			
	Filing Date		2005-10-26			
	First Named Inventor Lynne		nne Canne Bannen			
	Art Unit		1624			
	Examiner Name	Ebene	nezer O. Sackey			
	Attorney Docket Numb	er	02-280-F			

U.S.PATENTS											
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	of cited Document			Relevant Passages or Releva		
	1										
If you wisl	h to ac	ld additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.				
	xaminer   Cite   No										
Examiner Initial*		Publication Number	1 1						Relevant Passages or Releva		
	1										
If you wisl	h to ac	ld additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	butto	n.		
· · · · · · · · · · · · · · · · · · ·											
Examiner Initial*							Applicant of cited	e or	where Relevant Passages or Relevant	<b>T</b> 5	
	1	97/20824	WO		A1	1997-06-12	Agourdon Pharma				
	2	98/32748	wo		A1	1998-07-30	Hoffmann La Roche et al.				
	3	1 016 245	GB		A1	1966-01-05	ICI Ltd.				

/Fiona T. Powers/

07/14/2009

Receipt date: 12/09/2008			Application Number				10518110 - GAU: 1626					
			Filing Date				2005-10-26					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		First Named Inventor Lynne			e Canne Bannen	c Canne Bannen						
		Art Unit				1624						
		Examiner Name Ebene				ezer O. Sackey						
			Attorney Docket Number			02-280-F						
								L				
		T										
	4	98/43963	wo		A1	1998-10-08	3 4	Agourdon Pharma				
	5	01/55112	wo		A1	2001-08-02	2 4	American Cyanamid (	Co.			
	6	03/051825	WO		A1	2003-06-26	6 E	Exelixis, Inc.				
If you wis	n to a	ı dd additional Foreign	Patent Do	cument	 citation	ı informatio	n plea	ase click the Add bu	∟ utton			
						ERATURE	•					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item									<b>T</b> 5	
	1	FEIT et al., "Structure-activity studies on sulfamyl diuretics", Journal of Medicinal Chemistry, 15(4), 1972, 437-440.										
	2	SHAHRIPOUR, A. B. et al., "Structure-based design of caspase - 1 inhibitor containing a diphenyl ether sulfonamide", Biorganic & Medicinal Chemistry Letters, 11(20), 2001, 2779-2782.									·	
	3	NEALE, A. J. et al., "Internuclear cyclizations of aromatic sulfonyl chlorides. Tribenz [b,d,f] oxepin and tribenzo [b,d,f] thiepin", Tetrahedron, 21(6), 1299-313. , 1965.										
If you wis	h to a	l dd additional non-pat	ent literatui	e docu	ment ci	tation inforr	natior	n please click the A	dd bu	tton		
		·		EX	AMINE	R SIGNAT	URE					
Examiner Signature /Fiona T. Powers/						Date Considere	ed	07/14/2009				
		nitial if reference cons conformance and no										l
Standard ST <sup>4</sup> Kind of doo	7.3). <sup>3</sup> Foument	of USPTO Patent Docume For Japanese patent docu by the appropriate symbo anslation is attached.	ments, the ind	ication of	the year	of the reign of	f the Er	mperor must precede th	ne serial	number of	the patent do	ocument.